Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDAI NASDAQ:MGRM NASDAQ:NYXH NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDAISpectral AI$1.93-3.0%$2.41$0.82▼$3.25$53.19M0.9358,229 shs365,474 shsMGRMMonogram Orthopaedics$5.80+0.3%$4.79$1.92▼$6.02$234.85M0.69138,054 shs43,863 shsNYXHNyxoah$6.24-0.6%$7.30$5.55▼$11.87$213.90M1.61161,700 shs13,166 shsSGHTSight Sciences$4.06+0.5%$3.86$2.03▼$7.03$211.56M2.44130,463 shs59,857 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDAISpectral AI-5.24%-1.49%-21.03%+24.24%+35.37%MGRMMonogram Orthopaedics+2.66%+5.86%+2.30%+136.89%+121.03%NYXHNyxoah+1.78%-1.10%-16.04%-20.00%-25.33%SGHTSight Sciences-4.49%-1.94%+16.76%+8.89%-39.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDAISpectral AI3.1271 of 5 stars3.54.00.00.02.73.30.0MGRMMonogram Orthopaedics1.9001 of 5 stars1.85.00.00.03.11.70.6NYXHNyxoah2.193 of 5 stars3.53.00.00.01.60.80.6SGHTSight Sciences2.061 of 5 stars2.23.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDAISpectral AI 3.00Buy$3.5081.35% UpsideMGRMMonogram Orthopaedics 3.50Strong Buy$5.40-6.90% DownsideNYXHNyxoah 3.00Buy$15.00140.38% UpsideSGHTSight Sciences 2.43Hold$4.428.78% UpsideCurrent Analyst Ratings BreakdownLatest MDAI, SGHT, MGRM, and NYXH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/21/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.60 ➝ $4.508/8/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$3.00 ➝ $5.007/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.50 ➝ $4.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDAISpectral AI$29.58M1.74N/AN/A($0.34) per share-5.68MGRMMonogram Orthopaedics$370K636.90N/AN/A$0.21 per share27.62NYXHNyxoah$4.89M43.46N/AN/A$2.45 per share2.55SGHTSight Sciences$79.87M2.66N/AN/A$1.34 per share3.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDAISpectral AI-$15.31M-$0.69N/AN/AN/A-51.97%N/A-8.69%11/5/2025 (Estimated)MGRMMonogram Orthopaedics-$16.33M-$0.50N/AN/AN/AN/A-126.82%-96.87%11/13/2025 (Estimated)NYXHNyxoah-$64.10M-$2.30N/AN/AN/A-1,541.84%-79.18%-54.92%11/5/2025 (Estimated)SGHTSight Sciences-$51.51M-$0.96N/AN/AN/A-64.23%-59.38%-36.43%11/6/2025 (Estimated)Latest MDAI, SGHT, MGRM, and NYXH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NYXHNyxoah-$0.62-$0.63-$0.01-$0.63$1.33 million$1.58 million8/15/2025Q2 2025MGRMMonogram Orthopaedics-$0.11-$0.16-$0.05-$0.16N/AN/A8/12/2025Q2 2025MDAISpectral AI-$0.07-$0.10-$0.03-$0.31$5.44 million$5.07 million8/7/2025Q2 2025SGHTSight Sciences-$0.25-$0.23+$0.02-$0.23$18.18 million$19.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDAISpectral AIN/AN/AN/AN/AN/AMGRMMonogram OrthopaedicsN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDAISpectral AIN/A0.870.84MGRMMonogram OrthopaedicsN/A2.162.16NYXHNyxoah0.292.632.38SGHTSight Sciences0.5710.019.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDAISpectral AI67.08%MGRMMonogram Orthopaedics0.45%NYXHNyxoahN/ASGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipMDAISpectral AI30.70%MGRMMonogram Orthopaedics28.10%NYXHNyxoah17.11%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDAISpectral AI8326.73 million18.53 millionNot OptionableMGRMMonogram Orthopaedics2840.63 million29.21 millionNot OptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableSGHTSight Sciences21052.37 million36.19 millionOptionableMDAI, SGHT, MGRM, and NYXH HeadlinesRecent News About These CompaniesSight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare ConferenceAugust 26 at 4:05 PM | globenewswire.comWhat 4 Analyst Ratings Have To Say About Sight SciencesAugust 22, 2025 | benzinga.comCitigroup Boosts Sight Sciences (NASDAQ:SGHT) Price Target to $4.50August 22, 2025 | americanbankingnews.comSight Sciences price target raised to $4.50 from $3.60 at CitiAugust 21, 2025 | msn.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesAugust 14, 2025 | marketbeat.comSight Sciences’ Earnings Call: Balancing Growth and ChallengesAugust 13, 2025 | msn.comLake Street Upgrades Sight Sciences (SGHT)August 11, 2025 | msn.comWall Street Zen Upgrades Sight Sciences (NASDAQ:SGHT) to HoldAugust 10, 2025 | marketbeat.comSight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comSight Sciences (NASDAQ:SGHT) Upgraded to Buy at Lake Street CapitalAugust 9, 2025 | marketbeat.comSight Sciences, Inc. (SGHT) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSight Sciences Reports Q2 2025 Financial ResultsAugust 8, 2025 | tipranks.comCompared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key MetricsAugust 7, 2025 | zacks.comSight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue EstimatesAugust 7, 2025 | zacks.comSight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue GuidanceAugust 7, 2025 | globenewswire.comSight Sciences (SGHT) Projected to Post Earnings on ThursdayJuly 31, 2025 | marketbeat.comSight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% ...July 30, 2025 | manilatimes.netMSight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye DiseaseJuly 30, 2025 | globenewswire.comSight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye DiseaseJuly 29, 2025 | globenewswire.comSight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025July 24, 2025 | globenewswire.com7SGHT : The Analyst Verdict: Sight Sciences In The Eyes Of 4...July 15, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDAI, SGHT, MGRM, and NYXH Company DescriptionsSpectral AI NASDAQ:MDAI$1.93 -0.06 (-3.02%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.07 (+3.63%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.Monogram Orthopaedics NASDAQ:MGRM$5.80 +0.02 (+0.35%) Closing price 04:00 PM EasternExtended Trading$5.80 0.00 (-0.09%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was founded in 2015 and is headquartered in Austin, Texas.Nyxoah NASDAQ:NYXH$6.24 -0.04 (-0.64%) Closing price 04:00 PM EasternExtended Trading$6.36 +0.12 (+1.99%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Sight Sciences NASDAQ:SGHT$4.06 +0.02 (+0.50%) Closing price 04:00 PM EasternExtended Trading$4.06 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access